Global Necrobiosis Lipoidica Market – Industry Trends and Forecast to 2030

Necrobiosis Lipoidica Market Analysis and Size

Increasing cases of diabetes associated skin disorders enhance the necrobiosis lipoidica market. As per the International Diabetes Federation, diabetes is becoming more incident worldwide, accounting for 6.7 million deaths by 2021. Though the causes of necrobiosis lipoidica is still unknown, it can be associated with the blood vessel inflammation related to autoimmune factors. Additionally, selling campaigns initiated by the major market players is increasing the market progressively.  

Data Bridge Market Research analyses a growth rate in the necrobiosis lipoidica market in the forecast period 2023-2030. The expected CAGR of necrobiosis lipoidica market is tend to be around 6.20% in the mentioned forecast period. The market is valued at USD 4 billion in 2022, and it would grow upto USD 6.47 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Necrobiosis Lipoidica Market Scope and Segmentation

Market Definition

Necrobiosis lipoidica is the rare inflammatory granulomatous skin disorder that causes collagen degeneration. The condition is closely associated with the insulin dependent diabetes though it can occur in both types of diabetes and smoking people.  The features of necrobiosis lipoidica are reddish brown area of the skin mostly occurs in lower legs, plaques, skin bacterial infection, delayed healing of wounds, skin ulcers, skin patches with shiny, thinned and prominent blood vessels and others.

Global Necrobiosis Lipoidica Market Dynamics

Drivers

• Increasing Prevalence of Skin Infections

The increasing prevalence of skin infections is boosting the growth of the market. The most prevalent skin disease was warts (41·3%), which is followed by acne (19.2%) and contact dermatitis (15·0%). Globally, the overall point prevalence of any skin disease was 61.2%. Around 84.5 million U.S. citizens, which means one in four were impacted by skin disease. Thus, the risk of Necrobiosis Lipoidica Diabeticorum (NLD) rises in the region.

• Rising Clinical Research Activities

There has been many start-ups that are focusing on the improvement of the market. Also, much clinical research is helping in growth of the market. For instance, Quin is using science, engineering and design to help people who take insulin make the best possible decisions. The company uses a multi-factorial approach for the management of insulin doses. Quin is building an app that correlates daily life experience with data from diabetes devices and phones, and assists people regarding the insulin intake. It can create previously unseen insights into why blood glucose fluctuates so much and inspire new approaches to treatment and research. This factor improves the market growth.

Opportunities

• Increasing Cases of Diabetes

Around 422 million people globally have diabetes, the majority surviving in low-and middle-income countries, and 1.5 million deaths are directly related to diabetes each year. Both the number of cases and the incidence of diabetes have been progressively increasing during the last few years. Furthermore, China is the country with the highest number of diabetics, with about 141 million people suffering from the disease. By 2045, it is expected that China will have about 174 million people with diabetes. This increasing level stimulate the condition of necrobiosis lipoidica which increases the market growth. Thus, this factor helps in increasing the market growth.

• Growing Healthcare Expenditure And Government Support

The rising incidence of cancer, the growing awareness for the disease and the associated treatment is also enhancing. Numerous government initiatives tend to provide better and more convenient treatments along with favourable reimbursement policies that are anticipated to increase the industry growth. Additionally, growing acceptance of advanced therapies is projected to drive the market.

Restraints/Challenges

• Increased Expenditure of Treatment

The growing expenditure associated with the medications hamper the market growth. There are numerous oral, topical drugs that cost high and people in the developing and underdeveloped countries cannot afford the same. This can cause the under treatment of several patients. This impedes the market growth.

This necrobiosis lipoidica market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the necrobiosis lipoidica market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In 2022, Basilea Pharmaceutica Ltd announced the positive topline results for the Phase III ERADICATE study, assessing ceftobiprole in the treatment of adult patients with bacterial bloodstream infections which is caused by Staphylococcus aureus (SAB).
• In 2022, Paladin Labs Inc., a subsidiary of Endo International PLC launched the Xydalba, a 30-minute intravenous (IV) therapy for acute bacterial skin and skin structure infections (ABSSSI) that can be administered as a single- or two-dose.

Global Necrobiosis Lipoidica Market Scope

The necrobiosis lipoidica market is segmented on the basis of skin biopsy, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Skin Biopsy

• Skin Biopsy
• Histopathology
• Others

Treatment

• Therapy
• Drugs
• Others

Route of Administration

• Oral
• Topical
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Necrobiosis Lipoidica Market Regional Analysis/Insights

The necrobiosis lipoidica market is analyzed and market size insights and trends are provided by skin biopsy, treatment, route of administration, end-users and distribution channel as referenced above.

The major countries covered in the necrobiosis lipoidica market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for necrobiosis lipoidica market throughout the forecasted period due to the increasing presence of skilled professionals and increased expenditure on R&D and healthcare.

Asia-Pacific dominates the market because of the incidence of skin related disorders. Additionally, the healthy improvement in healthcare infrastructure boost the market growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Necrobiosis Lipoidica Market Share Analysis

The necrobiosis lipoidica market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to necrobiosis lipoidica market

Key players operating in the necrobiosis lipoidica market include:

• Kowa Pharmaceuticals America, Inc. (U.S.)
• Senju Pharmaceutical Co.,Ltd.(Japan)
• Novartis AG (Switzerland)
• AERIE PHARMACEUTICALS, INC. (U.S.)
• Redx Pharma Plc (U.K.)

SKU-52835